Paper Details

  1. Home
  2. Paper Details

An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.

Author: AtrashShebli, BhutaniManisha, HamadehIssam, PaulBarry, UsmaniSaad Z, VoorheesPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Daratumumab, a monoclonal antibody targeting CD38, has recently been approved for the treatment of multiple myeloma in both newly diagnosed and relapsed refractory settings. This review discusses the recent FDA approval of a subcutaneous formulation of daratumumab, which promises to decrease infusion times and infusion reactions in myeloma patients.
Paper Details　
Original Abstract of the Article :
A subcutaneous formulation of daratumumab, a human immunoglobulin G1 kappa monoclonal antibody targeting CD38, recently achieved FDA approval for both newly diagnosed and relapsed refractory multiple myeloma amid promises to decrease infusion times and rates of infusion reactions in myeloma patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17474086.2020.1795829

データ提供：米国国立医学図書館（NLM）

Subcutaneous Daratumumab: A New Frontier in Multiple Myeloma Treatment

Multiple myeloma, a complex and often aggressive blood cancer, is like a vast desert of challenges for patients and researchers. This research explores the potential of a new subcutaneous formulation of daratumumab, a monoclonal antibody targeting CD38, for the treatment of multiple myeloma. Researchers are seeking to optimize treatment strategies, enhancing the effectiveness and convenience of this promising therapy.

Subcutaneous Daratumumab: A More Convenient and Effective Approach

The study highlights the potential benefits of subcutaneous daratumumab, offering a more convenient and potentially effective way to administer this medication. Imagine discovering a hidden oasis in the desert, offering a refreshing and revitalizing source of relief. This new formulation may reduce infusion times, minimize side effects, and improve the overall patient experience.

Navigating the Desert of Cancer Treatment: Finding Hope in Innovation

This research underscores the ongoing efforts to improve treatment strategies for multiple myeloma. Like a camel seeking a new and more efficient path across the desert, researchers are constantly exploring innovative approaches to combat this challenging disease. This research provides hope for a more convenient and effective treatment option, potentially leading to improved outcomes and a better quality of life for patients with multiple myeloma.

Dr. Camel's Conclusion

This research showcases the promising potential of subcutaneous daratumumab for the treatment of multiple myeloma. Like a wise camel guide navigating the desert of cancer treatment, researchers are continuously seeking to optimize treatment strategies, offering hope for a more convenient, effective, and less burdensome approach. This research underscores the importance of continued innovation and research in the fight against this complex and challenging disease.

Date :
  1. Date Completed 2021-05-26
  2. Date Revised 2021-05-26
Further Info :

Pubmed ID

32659139

DOI: Digital Object Identifier

10.1080/17474086.2020.1795829

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.